Document Detail

Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures.
MedLine Citation:
PMID:  10361905     Owner:  NLM     Status:  MEDLINE    
OBJECT: To assess the value of secondary prevention with lipid lowering therapy following either balloon angioplasty (PTCA) or bypass surgery (CABG) in familial hypercholesterolemia patients, the correlation of the new evolution of stenotic lesions and therapeutically achieved cholesterol levels was studied in 50 patients. METHODS: All surviving patients were followed angiographically after 5 years, and findings were correlated with the annually determined total serum cholesterol (TC) levels. RESULTS: New coronary atherosclerotic plaques were not observed in 18 patients in whom the TC was controlled to <220 mg/dl but in 19 of 32 patients in whom the TC was >220 mg/dl, a new evolution of stenotic lesions was observed angiographically. CONCLUSION: The new evolution of stenotic lesions following revascularization in patients with FH can be controlled significantly by lipid lowering therapy to maintain a TC level of <220 mg/dl, and if diet alone can not achieve it, aggressive medication and even LDL apheresis might be justified.
S Fukuzawa; S Ozawa; M Inagaki; S Morooka; T Inoue
Related Documents :
20536495 - A comparison of efficacy and safety of vildagliptin and gliclazide in combination with ...
7768495 - The effects of the 3-hydroxy, 3-methylglutaryl coenzyme a reductase inhibitor pravastat...
8908525 - Comparison of four different treatment regimes in hirsutism related to polycystic ovary...
6420965 - Long-term treatment of onchocerciasis patients from the liberian rain-forest with low d...
8276185 - Gallstone recurrence after shock-wave therapy.
1294415 - Postpartum periarticular hip abscess with later coxitis caused by group b streptococcus.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Internal medicine (Tokyo, Japan)     Volume:  38     ISSN:  0918-2918     ISO Abbreviation:  Intern. Med.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-07-29     Completed Date:  1999-07-29     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9204241     Medline TA:  Intern Med     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  330-5     Citation Subset:  IM    
Division of Cardiology, Funabashi Municipal Medical Center, Chiba.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Anticholesteremic Agents / therapeutic use
Cholestyramine Resin / therapeutic use
Coronary Artery Bypass
Coronary Artery Disease / prevention & control*
Coronary Disease / therapy
Follow-Up Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hyperlipoproteinemia Type II / blood,  drug therapy*
Lipids / blood
Middle Aged
Probucol / therapeutic use
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 11041-12-6/Cholestyramine Resin; 23288-49-5/Probucol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adenosine 5'-triphosphate induced dilation of human coronary microvessels in vivo.
Next Document:  Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disea...